Related Experiment Video
Updated: Jul 16, 2026
07:31
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
Therapeutics for alcoholism: what's the future?
1Brain Injury & Repair Group, Howard Florey Institute & Centre for Neuroscience, University of Melbourne, Melbourne, Victoria, Australia. andrew.lawrence@hfi.unimelb.edu.au
Drug and Alcohol Review
|March 17, 2007
Summary
Developing effective medications is crucial for treating alcoholism, a relapsing condition. This review explores current and novel drugs to prevent alcohol relapse, aiming for better patient adherence and outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Alcoholism is a chronic, relapsing condition requiring effective therapeutic strategies.
- Current treatments for alcohol use disorders (AUD) have limitations in efficacy and adherence.
- Developing safe and effective anti-craving medications is a key goal in addiction research.
Purpose of the Study:
- To review preclinical findings on the mechanisms of existing anti-craving drugs for AUD.
- To identify novel pharmacological agents with potential for treating alcohol use disorders.
- To discuss strategies for improving medication adherence and preventing relapse in AUD patients.
Main Methods:
- Review of preclinical studies on pharmacological interventions for alcohol use disorders.
- Analysis of mechanisms of action for current and potential anti-craving medications.
- Synthesis of evidence regarding drug efficacy, safety, and adherence in AUD treatment.
Main Results:
- Preclinical data suggest mechanisms for current anti-craving medications.
- Several novel pharmacological agents show promise for future AUD treatment.
- Current strategies are suboptimal, highlighting the need for improved therapies.
Conclusions:
- Further development of pharmacological agents is needed to effectively treat alcohol use disorders.
- Combination therapies and novel drug candidates offer potential for relapse prevention.
- Future research should focus on developing safe, effective, and adherence-promoting medications for AUD.
More Related Videos
Related Concept Videos
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:28Depressants
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...